Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma

January 3, 2025

Opinion

Video

Panelists discuss how talquetamab demonstrates superior efficacy compared with physician-chosen treatments for patients with heavily pretreated multiple myeloma, with improved progression-free survival and response rates.

EP: 1.Brief Overview of Therapeutic Landscape for R/R MM

Now Viewing

EP: 2.Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma

EP: 3.MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab

EP: 4.Elranatamab Dosing Strategies: Implications for Community Practice

EP: 5.Navigating Post–CAR T Progression: Therapy Selection and Targeting

EP: 6.Bispecific Therapies in Relapsed/Refractory Multiple Myeloma

EP: 7.ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma

Video content above is prompted by the following:

Updated Comparative Effectiveness of Talquetamab vs Real World Physician’s Choice of Treatment in R/R MM
How do the comparative outcomes of talquetamab against real-world physician’s choice inform your approach to sequencing therapies?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!